Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Phase II Trial of Anti-PD1, TSR-042, as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

NCT03833479 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Cáncer de Ovario as lead sponsor.

NCT NCT03833479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03833479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Phase II Trial of Anti-PD1, TSR-042, as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation
Lead sponsor
Grupo Español de Investigación en Cáncer de Ovario
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 28, 2019
Completion date
July 31, 2028
Enrollment
134 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, cervical cancer